Publication

Article

Pharmacy Times

September 2014 Oncology
Volume80
Issue 9

Immunotherapy with Radiation Therapy Shows Promise in Treating Lung Cancer Tumors

The combined effect of immunotherapy with radiation showed strong results in treating tumors in lung cancer patients, according to the results of a study published August 15, 2014, in Radiation Oncology.

The researchers examined the use of a tumor-specific mRNA-based vaccination combined with radiation in 2 tumor models, a low immunogenic Lewis lung cancer (LLC) tumor, and a high-immunogenic E.G7-OVA. The study evaluated the molecular mechanism that was induced by the combination therapy through gene expression arrays and analyses of tumor-infiltrating cells.

In testing on mice, the researchers used messenger RNA (mRNA)-based cancer vaccines in the combination treatment in the LLC tumor model, which is resistant to different therapeutic regimens, such as Avastin, radiation, and adoptive T-cell transfer.

The researchers found that immunotherapy alone did not inhibit tumor growth, while radiation alone resulted in transient inhibition. The combination of the 2 therapies, however, resulted in a “strong synergistic antitumor effect,” which shows the efficacy of the treatment model in controlling tumor growth in a lowimmunogenic carcinoma. The treatment also increased CD4+, CD8+, and NKT cell infiltration of mouse tumors. The study authors concluded that the combination therapy provides a basis for developing more potent anticancer treatments.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com